筑波大学附属病院は、茨城県つくば市にある病院である。筑波大学附属の大学病院であり、総合周産期母子医療センターなどを持つ。特定機能病院。

During the past decade, University of Tsukuba Hospital conducted 39 clinical trials. In the 10-year time frame, 39 clinical trials started and 13 clinical trials were completed, i.e. on average, 33.3% percent of trials that started reached the finish line to date. In the past 5 years, 16 clinical trials started and 13 clinical trials were completed. i.e. 81.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "University of Tsukuba Hospital" #1 sponsor was "Abbott Medical Devices" with 4 trials, followed by "Janssen Pharmaceutical K.K." with 3 trials sponsored, "Pfizer" with 3 trials sponsored, "Takeda" with 3 trials sponsored and "Bayer" with 3 trials sponsored. Other sponsors include 22 different institutions and companies that sponsored additional 28 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "University of Tsukuba Hospital" #1 collaborator was "Japan Lung Cancer Society" with 2 trials as a collaborator, "Merck Sharp & Dohme LLC" with 2 trials as a collaborator, "Abbott" with 1 trials as a collaborator, "Alpha-A, Inc." with 1 trials as a collaborator and "EPS Corporation" with 1 trials as a collaborator. Other collaborators include 5 different institutions and companies that were collaborators in the rest 15 trials.

According to Clinical.Site data, the most researched conditions in "University of Tsukuba Hospital" are "Acute Ischemic Stroke" (2 trials), "Atrial Fibrillation" (2 trials), "Cancer" (2 trials), "Heart Failure" (2 trials) and "Ovarian Cancer" (2 trials). Many other conditions were trialed in "University of Tsukuba Hospital" in a lesser frequency.

Most popular intervention types in "University of Tsukuba Hospital" are "Drug" (30 trials), "Device" (10 trials), "Other" (4 trials), "Biological" (2 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (7 trials), "Pembrolizumab" (3 trials), "Epacadostat" (2 trials), "Rogaratinib (BAY1163877)" (2 trials) and "TAK-625" (2 trials). Other intervention names were less common.

The vast majority of trials in "University of Tsukuba Hospital" are 37 trials for "All" genders, 4 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "University of Tsukuba Hospital". 1 are not yet recruiting, 10 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 22 completed trials in University of Tsukuba Hospital, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in University of Tsukuba Hospital, 3 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 20 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 5 trials that are defined as “Not Applicable".